nach oben

Erschienen in:

01.03.2018 | Case report

Daratumumab

Hypertension: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Auszug

In a single-center safety study of 28 patients, one patient [age and sex not stated] was described, who developed hypertension during treatment with daratumumab [dose and duration of treatment to reaction onset not stated]. The patient, who had relapsed/refractory multiple myeloma, received daratumumab infusion 550mL for 90 minutes (200−450 mL/hr). Previously, the patient had received ten daratumumab infusions at standard rate. During the infusion (accelerated rate), the patient developed grade II hypertension. Subsequently, the infusion was paused. The patient received diuretic therapy and the hypertension resolved. …

Barr H, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Blood 130 (Suppl. 1): Dec 2017 [abstract] - USA

Titel: Daratumumab
Hypertension: case report
Publikationsdatum: 01.03.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-43971-8

Springer Medizin

Daratumumab

Hypertension: case report

Auszug

Weitere Artikel der Ausgabe 1/2018

Rituximab

Clarithromycin/dexamethasone/lenalidomide

Levamisole

Erlotinib

Clozapine

Ruxolitinib

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Rituximab

Clarithromycin/dexamethasone/lenalidomide

Levamisole

Erlotinib

Clozapine

Ruxolitinib